ctDNA Methylation Surveillance Enables Earlier Curative Treatment in Colorectal Cancer (FIND Tria): JCO | August 2026

Introduction:

Despite curative surgery for stage I–III colorectal cancer (CRC), 10–30% of patients develop recurrence, most commonly within the first two years. Conventional postoperative surveillance using CT scans and carcinoembryonic antigen (CEA) often detects recurrence only after metastatic disease has become less amenable to curative treatment. The Phase III FIND trial evaluated whether a dynamic surveillance strategy guided by circulating tumour DNA (ctDNA) methylation could detect recurrence earlier and increase the opportunity for curative-intent treatment.

Why was this study needed?

A significant proportion of patients develop recurrence despite curative surgery.

Standard CT and CEA surveillance frequently detect recurrence at an advanced, unresectable stage.

Earlier identification of minimal residual disease (MRD) could allow curative treatment of oligometastatic recurrence.

ctDNA methylation assays offer highly sensitive detection of tumor DNA before radiological recurrence becomes evident.

Prospective randomized evidence demonstrating improved clinical outcomes with ctDNA-guided surveillance has been lacking.

Results:

The Phase III FIND trial randomized 584 patients with nonmetastatic CRC to ctDNA methylation-guided surveillance or conventional CT-based follow-up.

Overall recurrence rates were similar between both groups, indicating that ctDNA surveillance did not increase the incidence of detected recurrence but enabled earlier diagnosis.

Patients in the ctDNA-guided group were twice as likely to undergo curative-intent treatment for recurrent disease compared with standard surveillance.

ctDNA-guided monitoring detected recurrence approximately 4 months earlier, creating an important therapeutic window before radiological progression.

Among patients with liver and/or lung metastases, ctDNA-guided surveillance resulted in significantly higher rates of curative metastasis-directed surgery.

Recurrences detected through ctDNA surveillance had more favorable disease characteristics, including fewer metastatic lesions, smaller tumors, and predominantly unilobar liver involvement, increasing the likelihood of successful surgical resection.

Long-term overall survival data are still awaited to determine whether earlier intervention ultimately translates into improved survival.

Clinical Impact:

The FIND trial is the first randomized Phase III study to demonstrate that ctDNA methylation-guided postoperative surveillance can significantly increase the proportion of patients receiving potentially curative treatment for recurrent colorectal cancer. Rather than simply identifying recurrence earlier, this strategy detects disease while metastases remain surgically treatable, potentially transforming postoperative follow-up. If longer-term survival benefits are confirmed, ctDNA-guided surveillance may redefine standard postoperative monitoring and accelerate the integration of molecular residual disease assessment into routine colorectal cancer care.

Bottom Line:

Dynamic ctDNA methylation-guided surveillance detects colorectal cancer recurrence nearly four months earlier than conventional follow-up, doubling the likelihood of curative-intent treatment for recurrent disease. The FIND trial represents a major step toward precision postoperative surveillance, although mature survival data are needed before widespread adoption.